The method of claim 4, wherein the concentration of budesonide is 2 mg/ml.

The method of claim 4, wherein the concentration of budesonide is 4 mg/ml.

A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 2 mg/ml, the PVP K25 is present at a concentration of 0.001% w/w, and the PEG-1000 is present at a concentration of 0.3% w/w. view more

A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 4 mg/ml, the PVP K25 is present at a concentration of 0.001% w/w, and the PEG-1000 is present at a concentration of 0.3% w/w. view more

The inhaler of claim 10, wherein an actuation of the inhaler delivers 80 μg budesonide.

The inhaler of claim 10, wherein an actuation of the inhaler delivers 160 μg budesonide.

The method of claim 16, wherein an actuation of the inhaler delivers 80 μg budesonide.

The method of claim 16, wherein an actuation of the inhaler delivers 160 μg budesonide.

The pharmaceutical suspension composition of claim 9, wherein the PEG-1000 is present at a concentration of 0.3% w/w.

A method of treating a respiratory disorder, the method comprising administering the pharmaceutical suspension composition of claim 10 to a patient identified as in need of treatment with the composition.

The composition according toclaim 1 wherein the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w.

The pharmaceutical composition according toclaim 1 in which the PVP is PVP K25.